Groundbreaking therapies are on the horizon as scientists explore new treatment options for rare genetic disorders, according to a new report by healthcare experts GBI Research.
The new report looks at Cystic Fibrosis (CF), Duchenne Muscular Dystrophy (DMD), Fabry disease and Pompe disease, which are all chronic, degenerative genetic disorders – fatal if left untreated. DMD is characterized by a decline in muscle function, leading most patients to die in their mid-twenties, while CF causes irreversible damage to lung tissue. Existing treatments are able to prolong life or reduce symptoms, but are not disease-modifying, and are therefore unable to significantly alter the path of the disease. Cures are therefore desperately sought, while drug treatments to counter symptoms remain a lucrative market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze